Use of pkc-iota inhibitors for the treatment of breast cancer
AssigneesUniversity of South Florida, The United States Government as represented by the Department of Veterans Affairs, University of Florida Research Foundation, Inc.
InventorsMildred Enid Acevedo-Duncan, Diondra Denise Hill, David A. Ostrov
Life of this patent
Estimating the term…
Abstract
The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells.
Claims20
A method of treating breast cancer or tumor comprising administering, to a subject in need of such treatment, an effective amount of a PKC-iota inhibitor, and, optionally, a pharmaceutical acceptable carrier.
A method of inhibiting proliferation of breast cancer or tumor cells, comprising administering to the breast cancer or tumor cells an effective amount of a PKC-iota inhibitor, and optionally, a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.